Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of balinatunfib in adults with moderate-to-severe ulcerative colitis
2025-520705-12-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Balinatunfib dose-ranging arm(s) with Placebo arm (2 arms). Primary endpoint: Clinical remission by modified Mayo Score at Week 12. Started Jun 2025; status: completed.
02
Drugs
balinatunfib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-520705-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520705-12-00.